

**July 24, 2018**

To
Listing Department
BSE Limited

Subject: Exclusive Service Agreement with Hongkong Thinkway Trading Limited for China, APAC & LATAM

Ref: Disclosure under Reg 30 of SEBI (LODR), Regulation, 2015 and Press Release

We are happy to announce that Vanta Bioscience Ltd. has entered into an exclusive agreement with Hongkong ThinkWay Trading Limited, Hongkong, to expand its business in the pre-clinical services sector in Greater China. The Company have also entered into non - exclusive agreements to cover the markets of Latin America (LATAM) and Asia Pacific (APAC) for Chemicals and Agrochemical business. These are lucrative markets and the Company expects over 25% of its revenues this year to come from this initiative.

The Company believes that this association will help in obtaining key clients and further business opportunities in China and will fuel the Company's growth prospects in years to come.

In terms of SEBI CIR/CFD/CMF/4/2015 dated September 09, 2015, we hereby submit the following information:

Name of the entity with whom Agreement is signed	Hongkong Thinkway Trading Limited
Area of Agreement	Exclusive Agreement for providing business consulting services and procuring sales for Vanta in Greater China, APAC and LATAM (Non-exclusive for APAC and LATAM)
Domestic/International	International – Greater China, APAC and LATAM
Share Exchange ratio	Not applicable – As this is a service agreement
Scope of Business Operation of Agreement	Providing business consulting services and procuring orders in Pre-clinical business for Vanta Bioscience Limited in China, APAC and LATAM




Research Center :
 K2-B, 11th Cross Street, SIPCOT Industrial Complex,
 Gummidipoondi, Thiruvallur District, Tamilnadu -601 201.
 Tel : 044 6790 1600

Details of Consideration Paid	As agreed between the Company and HTTL
Significant Terms And Conditions of Agreement	1. The Service Provider will be exclusive authorised representative of Company to market the services in China. 2. To generate Pre-clinical business for the Company in China, APAC and LATAM
Whether Agreement with Related Party	No
Size of the Company	SME
Rationale and Benefit Expected	Will help in obtaining key clients and bring in business opportunities in China and will fuel the Company's future growth prospects in years to come.

In this connection, the Trading Window for all designated persons as under Insider Trading Policy of the Company will be closed from Tuesday, July 24, 2018 to Friday, July 27, 2018 (both days inclusive).

This is for your information and dissemination to general public.

for Vanta Bioscience Limited
(Scrip Code: 540729 | Scrip ID: VANTABIO)


Zoheb Sayani
Company Secretary



Press Release

Vanta Bioscience expands to China, APAC & LATAM

Sign exclusive service partnership for China

China to add more than 25% in topline in current fiscal

24th July 2018; Hyderabad. Hyderabad based Vanta Bioscience Ltd., a full service preclinical contract research organization with research laboratories in Chennai, has entered into an exclusive agreement with Hongkong ThinkWay Trading Limited, Hongkong, to expand its business in the pre-clinical services sector in Greater China. The Company have also entered into non - exclusive agreements to cover the markets of Latin America (LATAM) and Asia Pacific (APAC) for Chemicals and Agrochemical business. These are lucrative markets and Vanta Bioscience expects over 25% of its revenues this year to come from this initiative.

The Company believes that this association will help in obtaining key clients and further business opportunities in China and will fuel the Company's growth prospects in years to come.

About this development, M. Dopesh Raja, Managing Director, Vanta Bioscience Ltd, explained that "Our expansion into China, APAC & LATAM markets will help us in securing long term contracts as we will be in a sweet spot of demand-supply gap in many of the countries in this region, thus paving the way for a robust and sustainable growth for Vanta Bioscience."

About Vanta Bioscience Limited

Vanta Bioscience Limited, a BSE Listed Company, is a preclinical contract research firm, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, it also provides risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. Besides, The Company also provides expert services for determination of health-based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharma sector. Among the major services of Vanta Bioscience is conducting of variety of in-vitro (cell, tissue & organisms) and in-vivo (animal) toxicology studies for its diverse clients as per regulatory requirements from across the world.

The Company has research laboratories in Chennai, India and is managed by industry veterans and experts. Complying with OECD GLP, ISO, AAALAC & USFDA GLP (21 CFR Part 58) guidelines, Vanta has been established as a center of excellence for OECD GLP toxicology services. More information can be availed on: www.vantabio.com.

For more information, kindly contact:

Priva Panvekar
Raka Reputation Management Services Pvt. Ltd.
Mobile: 7045654080

Vanta Bioscience Limited
Mobile: 9866272052

